FoRx Therapeutics Revenue and Competitors

Basel,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • FoRx Therapeutics's estimated annual revenue is currently $6.2M per year.(i)
  • FoRx Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • FoRx Therapeutics has 40 Employees.(i)
  • FoRx Therapeutics grew their employee count by 38% last year.

FoRx Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Senior Research Associate, Translational ResearchReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is FoRx Therapeutics?

FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. It is backed by a syndicate of investors that include the Novartis Venture Fund, Pfizer Ventures, M Ventures, Omega Funds and LSP Venture Capital. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.

keywords:N/A

N/A

Total Funding

40

Number of Employees

$6.2M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

FoRx Therapeutics News

2022-04-20 - A Guiding Hand For Biotech Start-Ups In Turbulent Times

One of them is FoRx Therapeutics AG, which is developing a new generation of cancer drugs focusing on novel DNA replication stress (DRS)...

2022-04-13 - In Vivo's 2022 Rising Leaders: Putting A Spotlight On Talent

He serves on the board of ViCentra, Aidence, Audion Therapeutics, ... including oncology companies FoRx Therapeutics and Anavo Therapeutics.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.3M40-25%N/A
#2
$7.8M4111%$210M
#3
$6.4M4121%N/A
#4
$5.1M4422%$17M
#5
$8.9M447%N/A